- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Leading sales enablement, prospecting and automation providers and technology solutions for the pharmaceutical industry | ||
| Mi | UK life science startups have trouble "scaling up" says Lord Vallance | ||
| Mi | KM Biologics' mpox vaccine approved for emergency use by WHO | ||
| Mi | Tris Pharma receives ex-US approvals for ADHD treatments | ||
| Mi | Veeva Commercial Summit: Increased investment in medical affairs by pharma companies | ||
| Mi | Parkinson's disease cases to reach 3.15 million in 7MM by 2033 | ||
| Mi | Pharmanovia signs license agreement for Lindis Biotech's catumaxomab | ||
| Mi | Wes Streeting says patients should view data sharing 'the same as taxes' | ||
| Mi | Daiichi Sankyo and AstraZeneca's Enhertu snubbed by UK's NICE for third time | ||
| Mi | AHA 2024: Phase III BROOKLYN trial - safety and efficacy of obicetrapib in HeFH patients | ||
| Mi | FDA issues CRL to Astellas' IZERVAY sNDA for geographic atrophy | ||
| Di | Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy | ||
| Di | Aclaris Therapeutics secures global rights to Biosion's antibodies | ||
| Di | BMS CFO backs "resilient" pharma industry amid RFK's impending governance | ||
| Di | Does Southeast Asia have a growing role in vaccine development? | ||
| Di | AHA 2024: CV effectiveness of GLP-1RA + Empagliflozin therapy in adults with T2D | ||
| Di | Novartis strengthens radiopharma leadership with Ratio Therapeutics deal | ||
| Di | ReCode to secure funds for cystic fibrosis gene correction treatments | ||
| Di | AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and obesity in SUMMIT | ||
| Di | CHMP recommends AstraZeneca's Tagrisso for EU approval for NSCLC | ||
| Mo | AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership | ||
| Mo | Intellia's gene editing therapy shows early potential in rare heart condition | ||
| Mo | Sandoz's Afqlir gains EC marketing authorisation for retinal diseases | ||
| Mo | AbbVie's Elahere wins European approval for certain ovarian cancers | ||
| Mo | FDA approves Syndax's Revuforj to treat leukaemia |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
